Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Alirocumab in Patients With Homozygous Familial Hypercholesterolemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Dec 2022
Price :
$35
*
At a glance
- Drugs Alirocumab (Primary)
- Indications Hyperlipoproteinaemia type IIa
- Focus Registrational; Therapeutic Use
- Acronyms ODYSSEY HoFH
- Sponsors Regeneron Pharmaceuticals
- 14 Jul 2020 Results published in the Journal of the American College of Cardiology
- 30 Apr 2020 Status changed from active, no longer recruiting to completed.
- 30 Mar 2020 According to an Regeneron Pharmaceuticals media release, the company plans to submit these data as the basis of regulatory submissions with the FDA in the second quarter of 2020.